Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma

Neurosurgery
Drew PrattEdjah K Nduom

Abstract

Checkpoint inhibition has demonstrated clinical efficacy in a variety of solid tumors. Reports of programmed death ligand 1 (PD-L1) expression in glioblastoma are highly variable (ranging from 6% to 88%) and its role as a prognostic marker has yielded conflicting results. To validate the prevalence and prognostic role of PD-L1 expression in a large cohort of diffuse gliomas according to the 2016 revised WHO classification. Using tissue microarrays, we compared 5 PD-L1 monoclonal antibodies (n = 56) and validated expression (n = 183) using quantitative immunohistochemistry (IHC) and RNA in situ hybridization (RISH). Expression data from The Cancer Genome Atlas (TCGA) and published studies were compared with clinical outcome. Multiplexed immunophenotyping was used to identify PD-L1+ cell populations in post-treatment glioblastoma. Using a 5% cut-off, PD-L1 expression was significantly associated with a poor prognosis in both histologically defined (n = 125, log-rank P < .001) and recurrent isocitrate dehydrogenase (IDH)-wildtype glioblastoma (n = 60, log-rank P = .015). PD-L1 remained a significant negative prognosticator in Cox regression analysis (hazard ratio: 1.96, P = .021). Analysis of TCGA data confirmed decreased overall ...Continue Reading

References

Apr 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel P CahillDavid N Louis
Jun 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anastasia MuratMonika E Hegi
Feb 12, 2009·Molecular Cancer Research : MCR·Subha MadhavanKenneth Buetow
Nov 19, 2009·Cancer Research·Lonneke A M GravendeelPim J French
Jul 30, 2010·Neuro-oncology·Adam WuAmy B Heimberger
Mar 30, 2011·Glia·Nikki A CharlesHelmut Kettenmann
Jun 4, 2013·The New England Journal of Medicine·Jedd D WolchokMario Sznol
Aug 30, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Yawei LiuShohreh Issazadeh-Navikas
Apr 10, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Janis M TaubeRobert A Anders
Oct 31, 2014·Neuro-oncology·Anna Sophie BerghoffWolfgang Wick
Jun 2, 2015·The New England Journal of Medicine·Dung T LeLuis A Diaz
Sep 2, 2015·Neuro-oncology·Edjah K NduomAmy B Heimberger
Oct 31, 2015·Neuro-oncology·Edjah K NduomAmy B Heimberger
Mar 24, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric BouffetUri Tabori
Jun 9, 2016·Nature Genetics·Jiguang WangRaul Rabadan
Jul 3, 2016·Neuro-oncology·Sarah T GarberAmy B Heimberger
Aug 20, 2016·JAMA Oncology·Patricia GauleDavid L Rimm
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Dec 30, 2016·Neuro-oncology·Robert L BowmanMassimo Squatrito
Mar 14, 2017·Laboratory Investigation; a Journal of Technical Methods and Pathology·Anna GieryngBozena Kaminska
May 14, 2017·Journal of Neuro-oncology·Marc C Chamberlain, Bryan T Kim
May 23, 2017·Neuro-oncology·Anna Sophie BerghoffMatthias Preusser
Jun 22, 2017·The New England Journal of Medicine·David P CarboneUNKNOWN CheckMate 026 Investigators
Jul 7, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel L AdamsSteven H Lin
Aug 10, 2017·Journal of Neuropathology and Experimental Neurology·Drew PrattMartha Quezado
Aug 17, 2017·Nature·Riccardo MezzadraTon N M Schumacher
Nov 9, 2017·The New England Journal of Medicine·Lynn M Schuchter
Nov 18, 2017·Journal of Neuro-oncology·Kyu Sang LeeGheeyoung Choe

❮ Previous
Next ❯

Citations

Mar 13, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Bozena KaminskaBartlomiej Gielniewski
Oct 11, 2019·Drugs·Rimas V LukasAdam M Sonabend
Jun 1, 2020·Journal for Immunotherapy of Cancer·John P LynesEdjah K Nduom
Dec 21, 2018·Frontiers in Oncology·John LynesEdjah Nduom
Jan 29, 2019·Frontiers in Pharmacology·Ruo Qiao ChenXiao Qian Chen
Sep 18, 2021·Neuropathology and Applied Neurobiology·Gayaththri Vimalathas, Bjarne Winther Kristensen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.